IM-4 Impact of oHSV activated NOTCH signaling in tumor microenvironment and its impact on anti-tumor immunity

Oncolytic herpes simplex virus-1 (oHSV) is novel FDA-approved immunotherapy for advanced melanoma patients in US. Also, oHSV is recently approved for the treatment of recurrent GBM in Japan. We have shown that oHSV treatment of GBM cells induces NICD cleavage and NOTCH activation in adjacent uninfec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshihiro, Otani, Yoo, Ji Young, Lawler, Sean E, Chiocca, Antonio E, Kaur, Balveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648241/
http://dx.doi.org/10.1093/noajnl/vdab159.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648241/
http://dx.doi.org/10.1093/noajnl/vdab159.027

Ejemplares similares